Literature DB >> 10589782

Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?

R L Hong1, C J Huang, Y L Tseng, V F Pang, S T Chen, J J Liu, F H Chang.   

Abstract

Sterically stabilized liposome is characterized by a surface coating of polyethylene glycol (PEG) or other polymers that can reduce opsonization of the liposome by plasma proteins. It has a higher plasma area under the concentration-time curve (AUC), which is believed to correlate with better therapeutic efficacy. However, the presence of large molecules on the liposomal surface may reduce the interactions of liposomes with cells and hinder entry of liposomes into the tumor tissue. Using a stable liposomal system composed of distearoyl phosphatidylcholine/cholesterol, we examined the effect of PEG (Mr 2000) on the pharmacokinetics and on the efficacy of liposomal doxorubicin with C-26 syngeneic tumor model in BALB/c mice. The plasma AUC of liposomal doxorubicin with 6 mol-% PEG-modified distearoyl phosphatidylethanolamine (PEG-DSPE) was approximately twice that of liposomal doxorubicin without PEG at various dosages, regardless of whether the mice were tumor-bearing. Paradoxically, the group of mice treated with liposomal doxorubicin without PEG had higher tumor doxorubicin concentrations. The 72-h tumor AUC was 1.44 times that of liposomal doxorubicin with 6% PEG-DSPE. The tumor-accumulation efficiency (AUC(Tumor)/AUC(Plasma)) of liposomal doxorubicin without PEG was 0.87, and this was more than twice that of the liposomal doxorubicin with 6% PEG-DSPE (0.31). At a dose of 10 mg/kg, although both liposomal groups were better than the free drug group in terms of clinically relevant parameters, including toxicity, tumor shrinkage, and survival, there was no difference between the two liposomal drug groups. In this stable liposome system, surface coating with PEG offered no benefit for liposomal doxorubicin in the C-26 tumor model. To enhance the therapeutic index of liposomal doxorubicin, simply increasing plasma AUC by surface coating with PEG may not be satisfactory.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589782

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  66 in total

1.  In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™.

Authors:  Wubeante Yenet Ayen; Neeraj Kumar
Journal:  Pharm Res       Date:  2012-06-06       Impact factor: 4.200

2.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

Review 3.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

4.  Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered poly(ethylene glycol) shedding.

Authors:  Corbin Clawson; Linh Ton; Santosh Aryal; Victoria Fu; Sadik Esener; Liangfang Zhang
Journal:  Langmuir       Date:  2011-08-11       Impact factor: 3.882

5.  Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles.

Authors:  Pia L Rodriguez; Takamasa Harada; David A Christian; Diego A Pantano; Richard K Tsai; Dennis E Discher
Journal:  Science       Date:  2013-02-22       Impact factor: 47.728

Review 6.  Application of polysaccharides for surface modification of nanomedicines.

Authors:  Kyung-Oh Doh; Yoon Yeo
Journal:  Ther Deliv       Date:  2012-12

Review 7.  Designer lipids for drug delivery: from heads to tails.

Authors:  Aditya G Kohli; Paul H Kierstead; Vincent J Venditto; Colin L Walsh; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-06       Impact factor: 9.776

Review 8.  Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Authors:  Alberto Gabizon; Hilary Shmeeda; Yechezkel Barenholz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Pegylated liposomal doxorubicin in ovarian cancer.

Authors:  Robert Strother; Daniela Matei
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

10.  Formulation of novel lipid-coated magnetic nanoparticles as the probe for in vivo imaging.

Authors:  Huey-Chung Huang; Po-Yuan Chang; Karen Chang; Chao-Yu Chen; Chung-Wu Lin; Jyh-Horng Chen; Chung-Yuan Mou; Zee-Fen Chang; Fu-Hsiung Chang
Journal:  J Biomed Sci       Date:  2009-09-21       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.